Dianthus Therapeutics is developing novel therapies for autoimmune diseases. The Executive Director, Head of Bioanalytical Sciences will own the bioanalytical strategy and execution across research, translational, and clinical development, serving as the senior scientific authority for assays and biomarker work.
What you'll do
Define and execute the company wide bioanalytical strategy and capability roadmap
Provide scientific oversight for assay strategy, development, validation, and data interpretation
Ensure assays are fit for purpose, compliant with regulatory expectations, and support key program decisions
Lead resolution of complex assay and vendor issues in partnership with Quality and external labs
Own or oversee regulatory Content for submissions and health authority interactions
Build and develop the Bioanalytical Sciences function, including recruitment and performance management
What they're looking for
PhD or advanced equivalent in a relevant scientific discipline
15 or more years of progressive bioanalytical experience with leadership responsibilities
Proven track record leading bioanalytical strategy across programs and development stages
Deep expertise in method development, qualification, validation, transfer, and data review
Strong knowledge of platforms such as PK, PD, biomarker assays, ligand binding, and LC MS/MS
Experience with GLP/GCP, data integrity, inspection readiness, and regulatory submissions
For applicants in Nigeria
The listing states remote work is possible; confirm any country specific eligibility during interview
The listing does not specify a timezone requirement; confirm expectations before interviewing
The listing does not specify employment type or pay currency; confirm these details during process
Summarized by RemoteWork from the original listing. Always confirm details on the employer’s page.
Ready to apply?
Your application goes straight to Dianthus Therapeutics, on their own hiring page.
Dianthus Therapeutics develops complement antibody therapies for patients with severe autoimmune diseases. Its investors include 5AM Ventures, Fairmount, Fidelity and Venrock.